Evidence map›Paper›PMID 31827267›Full record

ReviewNature reviews. Neurology2020

Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.

Steven M Greenberg, Brian J Bacskai, Mar Hernandez-Guillamon, Jeremy Pruzin, Reisa Sperling, Susanne J van Veluw

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06960538 (PRIORITY), which is not on this map. Cited by 569 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
569citing papers in PubMed, 6 pooled it
42.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06960538 completednot on this mapstarted 2021, after this paper: background citation

PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2021 to 2025Enrolled200ConditionsCerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
3 · Its place in the literature

Who cites it

569 citing papers in PubMed, 6 syntheses or guidelines pooled it, 884 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Guideline
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  10. Trial
  11. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  12. Article
  13. Review
  14. Review
  15. Proteomic dysregulation associated with cerebral amyloid angiopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Cognition in Cardiovascular Disease.Current neurology and neuroscience reports · 2026
    Review
  18. Article
  19. Review
  20. Article

509 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Steven M GreenbergDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. sgreenberg@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-1792-8887
Brian J BacskaiDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mar Hernandez-GuillamonNeurovascular Research Laboratory, Institut de Recerca, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jeremy PruzinCenter for Alzheimer Research and Treatment, Brigham & Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Reisa SperlingCenter for Alzheimer Research and Treatment, Brigham & Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Susanne J van VeluwDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USBrigham and Women's Hospital · USUniversitat Autònoma de Barcelona · ES

Funding

VCID Biomarkers Coordinating CenterU24NS100591 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg · 2016 to 2026
$19.8M
Vascular Dysfunction in Cerebral Amyloid AngiopathyR01AG026484 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GREENBERG, STEVEN M · 2005 to 2019
$7.5M
CEREBRAL AMYLOID ANGIOPATHY AND MECHANISMS OF BRAIN AMYLOID ACCUMULATIONR01NS096730 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BACSKAI, BRIAN J, GREENBERG, STEVEN M · 2016 to 2020
$5.7M
Cerebral microvascular lesions and vascular and neuronal networksRF1NS110054 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BACSKAI, BRIAN J · 2018 to 2020
$2.7M
NIA NIH HHS R01 AG026484NINDS NIH HHS R01 NS096730NINDS NIH HHS RF1 NS110054NINDS NIH HHS U24 NS100591
6 · The paper itself

Abstract

The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. The pathogenic pathways of CAA and AD intersect at the levels of Aβ generation, its circulation within the interstitial fluid and perivascular drainage pathways and its brain clearance, but diverge in their mechanisms of brain injury and disease presentation. Here, we review the evidence for and the pathogenic implications of interactions between CAA and AD. Both pathologies seem to be driven by impaired Aβ clearance, creating conditions for a self-reinforcing cycle of increased vascular Aβ, reduced perivascular clearance and further CAA and AD progression. Despite the close relationship between vascular and plaque Aβ deposition, several factors favour one or the other, such as the carboxy-terminal site of the peptide and specific co-deposited proteins. Amyloid-related imaging abnormalities that have been seen in trials of anti-Aβ immunotherapy are another probable intersection between CAA and AD, representing overload of perivascular clearance pathways and the effects of removing Aβ from CAA-positive vessels. The intersections between CAA and AD point to a crucial role for improving vascular function in the treatment of both diseases and indicate the next steps necessary for identifying therapies.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainCerebral Amyloid AngiopathyHumansPlaque, AmyloidSignal TransductionAmyloid beta-Peptides

Identifiers

PMID31827267
PMCPMC7268202
OpenAlexW2995183059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.